ライフサイエンスコーパス: dideoxyadenosine

1 1b), was 3 times more potent than beta-2',5'-dideoxyadenosine.

2 blocked by the adenyl cyclase inhibitor 2'5'-dideoxyadenosine.

3 s blocked by pertussis toxin and mimicked by dideoxyadenosine.

4 loop (formoterol AUC in the presence of 2'5'-dideoxyadenosine 0.64 +/- 0.03, or BAPTA-AM 0.45 +/- 0.2

5 Conversely, the adenylate cyclase inhibitor, dideoxyadenosine (10 microM) and the protein kinase A in

6 ated by the adenylyl cyclase inhibitor 2',5'-dideoxyadenosine (10(-5) to 10(-4) mol/L).

7 Protected 3'-phosphoryl derivatives of 2',5'-dideoxyadenosine (2',5'-dd-Ado) and beta-l-2',5'-dd-Ado,

8 s potency typically followed the order 2',5'-dideoxyadenosine (2',5'-ddAdo) > beta-adenosine > 9-(cyc

9 ished by co-treatment with losartan or 2',5'-dideoxyadenosine (2',5'-DOA, an adenylyl cyclase inhibit

10 c cross-linking to the catalytic site, 2',5'-dideoxyadenosine 3'-[gamma-(1-methylimidazole)-triphosph

11 2',5'-Dideoxyadenosine 3'-di- and triphosphates were tested as

12 -tetraphosphate (2'-deoxy-3'-A4P) and 2', 5'-dideoxyadenosine 3'-tetraphosphate (2',5'-dideoxy-3'-A4P

13 ine 3'-monophosphate (2'-d-3'-AMP) and 2',5'-dideoxyadenosine 3'-triphosphate (2',5'-dd-3'-ATP).

14 At sAC, 2',5'-dideoxyadenosine 3'-triphosphate was the most potent com

15 und that L-carbocyclic 2',3'-didehydro-2',3'-dideoxyadenosine (34) exhibited potent anti-HBV activity

16 ted by the stoichiometric formation of 3',5'-dideoxyadenosine-4',5'-ene as the nucleoside cleavage pr

17 orporation of the diphosphate of PMPA, 2',3'-dideoxyadenosine 5'-triphosphate (ddATP), and dATP catal

18 cyclase activator, and was not attenuated by dideoxyadenosine (5 nmol; n = 4), an adenylate cyclase i

19 beta-L-2',3'-Dideoxyadenosine-5'-triphosphate (beta-L-2', 3'-dd-5'-AT

20 suggests that AATP could be used as a 2',3'-dideoxyadenosine-5'-triphosphate (ddA) surrogate.

21 trendipine, a Ca2+ channel blocker, or 2',5'-dideoxyadenosine, a P-site antagonist of transmembrane a

22 hCG in preventing NF-kappaB activation, and dideoxyadenosine, an adenylate cyclase inhibitor, preven

23 2',5'-dideoxyadenosine, an inhibitor of adenylyl cyclase, prev

24 Dideoxyadenosine and H-8 reversed the effect, and dibuty

25 yclase, two inhibitors of its activity, 2'5'-dideoxyadenosine and SQ22536, were used.

26 -deoxythymidine, beta-D-2'-ara-fluoro-2', 3'-dideoxyadenosine, and beta-L-2',3'-dideoxy-3'-thiacytidi

27 27 and the adenylyl cyclase inhibitor 2',5'-dideoxyadenosine but were unaffected by IBMX.

28 r (U0126) or the adenylate cyclase inhibitor dideoxyadenosine (ddA) abolished the butyrate-induced: (

29 The AC inhibitor dideoxyadenosine (DDA) increased cell apoptosis and redu

30 2',3'-dideoxy-5-fluorocytidine (FddC), 2',3'-dideoxyadenosine (ddA), and 2'-beta-fluoro-2',3'-dideoxy

31 binofuranyl-guanosine, dideoxyinosine (ddI), dideoxyadenosine (ddA), didehydrothymidine (d4T), or pho

32 ated with adenylate cyclase inhibitors 2',3'-dideoxyadenosine (DDA), MDL-12330A (MDL), nicotinic acid

33 lase inhibitors nicotinic acid (NIC-A), 2',3'dideoxyadenosine (DDA), or MDL-12330A (MDL); (iii) the g

34 ase inhibitors nicotinic acid (NIC-A), 2',3'-dideoxyadenosine (DDA), or MDL-12330A.

35 thrine, the adenylyl cyclase inhibitor 2',5'-dideoxyadenosine (ddA), or the calcium chelators 3,4,5-t

36 ,536 [9-(tetrahydrofuryl)-adenine] and 2',5'-dideoxyadenosine (ddAd) are effective and potent AC inhi

37 the 5'-triphosphate of 2'-beta-fluoro-2',3'-dideoxyadenosine (F-ddA, lodenosine), a new anti-HIV dru

38 oxyadenosine (ddA), and 2'-beta-fluoro-2',3'-dideoxyadenosine (FddA)] and 9-(2-phosphonylmethoxyethyl

39 d AC activity and cAMP production with 2'-5' dideoxyadenosine, however, PACAP no longer increased ace

40 eoxythymidine and beta-D-2'-ara-fluoro-2',3'-dideoxyadenosine nucleotides had IC50 values for strand

41 e of extracellular Ca2+ and blocked by 2',5'-dideoxyadenosine or 3-isobutyl-1-methylxanthine, an inhi

42 adenylate cyclase type 5 (AC-5) using 2',5'-dideoxyadenosine or knock-down of AC-5 expression by int

43 Inhibition of adenylyl cyclase with dideoxyadenosine or PKA with either H89 or RpcAMPs block

44 ne with an adenylyl cyclase inhibitor (2',5'-dideoxyadenosine) or a protein kinase A inhibitor (H89)

45 In addition, 2',5'-dideoxyadenosine reduced the wild-type current to the le

46 ion of the adenylate cyclase inhibitor 2',5'-dideoxyadenosine to these cells decreased intracellular

47 rotein signaling), in combination with 2',5'-dideoxyadenosine treatment.

48 hates, and the reaction was not inhibited by dideoxyadenosine triphosphate or aphidicolin.

49 lished by the adenyl cyclase inhibitor 2',5'-dideoxyadenosine, while dose-dependent NO release was ev

50 ubation with the adenylate cyclase inhibitor dideoxyadenosine, with the protein kinase A (PKA) inhibi